Skip to content

Västra Hamnen initiates coverage of Xintela

Xintela is a biopharma company with two assets in clinical development phase. The company focuses on stem cell therapy and cancer therapy based on the cell surface receptor integrin α10β1. We initiate coverage with a fair value of SEK 1.30 per share.

Link to report: xintela-initialanalys-231201.pdf (